Funding for this research was provided by:
National Medical Research Council (NMRC/CSAINV20nov-0021)
Duke-NUS Medical School (Oncology Academic Program Goh Foundation Proton Research Programme)
National Cancer Centre of Singapore (Cancer Fund, Kua Hong Pak Head, Neck Cancer Research Programme)
Article History
Received: 6 October 2023
Accepted: 8 November 2023
First Online: 28 November 2023
Declarations
:
: Not applicable.
: Not applicable.
: The authors declare no direct conflict of interest for this work.Melvin L.K. Chua reports personal fees from Astellas, Janssen, Pfizer, MSD, Varian, IQVIA, Telix Pharmaceuticals; personal fees and research funding to institution from Bayer and BeiGene; personal fees and non-financial support from AstraZeneca; non-financial support from Decipher Biosciences; consults for immunoSCAPE Inc. and PVMed; and is a co-inventor of the patent of a High Sensitivity Lateral Flow Immunoassay For Detection of Analyte in Sample (10202107837 T), Singapore and serves on the Board of Directors of Digital Life Line Pte Ltd that owns the licensing agreement of the patent, outside the submitted work.